Literature DB >> 12368350

Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses.

Christoph Sarrazin1, Eva Herrmann, Katharina Bruch, Stefan Zeuzem.   

Abstract

Presumably due to the capability of the hepatitis C virus (HCV) to evade the antiviral effects of alpha interferon, treatment is ineffective in more than half of chronically genotype HCV type 1 (HCV-1)-infected patients. Previous approaches to correlate the number of amino acid mutations within regions of HCV nonstructural (NS)-5A protein with virologic treatment response provided conflicting results. In the present study, we developed a new mathematical model to investigate NS5A sequences of HCV-1-infected patients. The mean number of all mutations within the complete NS5A protein was significantly higher in virologic responders compared to nonresponders (P = 0.008 and P = 0.0001 for amino acid residues predicted on the surface of the NS5A protein). Differences did not achieve statistical significance for NS5A regions that are currently assumed to be functionally relevant (e.g., the interferon sensitivity-determining region, the RNA-activated protein kinase-binding domain, etc.). Analyses of smoothed mutational frequencies showed that the number of mutations in other NS5A regions correlated with virologic response. Such a correlation was observed for both genuine and randomly generated NS5A sequences. The existence of local accumulations of mutations within genuine NS5A isolates that truly correlated with treatment response was defined by a refined test procedure. Upon considering the predicted residue accessibility, we identified the main focus of mutations correlating with treatment response to be the sequence from amino acids 2350 to 2370. Thus, evaluation of NS5A mutations in correlation with treatment response is improved by consideration of functional and predicted conformational amino acid properties. As shown by simulations with randomly generated sequences, multiple analyses of simple counts of local NS5A amino acid mutations and correlation with treatment response are insufficient. For improvement of mutational analysis, a refined specific functional data test procedure is proposed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12368350      PMCID: PMC136596          DOI: 10.1128/jvi.76.21.11079-11090.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Purification and characterization of the NS3 serine protease domain of hepatitis C virus expressed in Saccharomyces cerevisiae.

Authors:  W Markland; R A Petrillo; M Fitzgibbon; T Fox; R McCarrick; T McQuaid; J R Fulghum; W Chen; M A Fleming; J A Thomson; S P Chambers
Journal:  J Gen Virol       Date:  1997-01       Impact factor: 3.891

2.  HIV-1 Tat directly interacts with the interferon-induced, double-stranded RNA-dependent kinase, PKR.

Authors:  N A McMillan; R F Chun; D P Siderovski; J Galabru; W M Toone; C E Samuel; T W Mak; A G Hovanessian; K T Jeang; B R Williams
Journal:  Virology       Date:  1995-11-10       Impact factor: 3.616

3.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

4.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.

Authors:  N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; Y Ogura; N Izumi; F Marumo; C Sato
Journal:  N Engl J Med       Date:  1996-01-11       Impact factor: 91.245

5.  Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response.

Authors:  C Sarrazin; T Berg; J H Lee; B Rüster; B Kronenberger; W K Roth; S Zeuzem
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

6.  Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis.

Authors:  C François; G Duverlie; D Rebouillat; H Khorsi; S Castelain; H E Blum; A Gatignol; C Wychowski; D Moradpour; E F Meurs
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

7.  Cleavage of hepatitis C virus nonstructural protein 5A by a caspase-like protease(s) in mammalian cells.

Authors:  S Satoh; M Hirota; T Noguchi; M Hijikata; H Handa; K Shimotohno
Journal:  Virology       Date:  2000-05-10       Impact factor: 3.616

8.  The N-terminal region of hepatitis C virus-encoded NS5A is important for NS4A-dependent phosphorylation.

Authors:  S I Asabe; Y Tanji; S Satoh; T Kaneko; K Kimura; K Shimotohno
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

9.  Characterization of the nuclear localization signal and subcellular distribution of hepatitis C virus nonstructural protein NS5A.

Authors:  Y Ide; L Zhang; M Chen; G Inchauspe; C Bahl; Y Sasaguri; R Padmanabhan
Journal:  Gene       Date:  1996-12-05       Impact factor: 3.688

10.  Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region.

Authors:  N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; N Izumi; F Marumo; C Sato
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

View more
  15 in total

Review 1.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

Review 2.  The quasispecies nature and biological implications of the hepatitis C virus.

Authors:  Sarah L Fishman; Andrea D Branch
Journal:  Infect Genet Evol       Date:  2009-08-08       Impact factor: 3.342

3.  Assessment of hepatitis C virus protein sequences with regard to interferon/ribavirin combination therapy response in patients with HCV genotype 1b.

Authors:  Sanja Glisic; Nevena Veljkovic; Snezana Jovanovic Cupic; Nada Vasiljevic; Jelena Prljic; Branislava Gemovic; Vladimir Perovic; Veljko Veljkovic
Journal:  Protein J       Date:  2012-02       Impact factor: 2.371

4.  Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C.

Authors:  Kazuaki Chayama; C Nelson Hayes; Kentaro Yoshioka; Hisataka Moriwaki; Takashi Okanoue; Shotaro Sakisaka; Tetsuo Takehara; Makoto Oketani; Joji Toyota; Namiki Izumi; Yoichi Hiasa; Akihiro Matsumoto; Hideyuki Nomura; Masataka Seike; Yoshiyuki Ueno; Hiroshi Yotsuyanagi; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2011-01-19       Impact factor: 7.527

Review 5.  Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.

Authors:  Shinya Maekawa; Nobuyuki Enomoto
Journal:  J Gastroenterol       Date:  2009       Impact factor: 7.527

6.  Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences.

Authors:  M Pascu; P Martus; M Höhne; B Wiedenmann; U Hopf; E Schreier; T Berg
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

Review 7.  An insight into the diagnosis and pathogenesis of hepatitis C virus infection.

Authors:  Mohammad Irshad; Dhananjay Singh Mankotia; Khushboo Irshad
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

8.  The hepatitis C virus NS5A protein and response to interferon alpha: mutational analyses in patients with chronic HCV genotype 3a infection from India.

Authors:  Ankur Goyal; Wolf P Hofmann; Eva Hermann; Stella Traver; Syed S Hissar; Naveen Arora; Hubert E Blum; Stefan Zeuzem; Christoph Sarrazin; Shiv K Sarin
Journal:  Med Microbiol Immunol       Date:  2006-09-06       Impact factor: 3.402

9.  Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.

Authors:  P Muñoz de Rueda; J Casado; R Patón; D Quintero; A Palacios; A Gila; R Quiles; J León; A Ruiz-Extremera; J Salmerón
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

Review 10.  Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.

Authors:  Ahmed El-Shamy; Hak Hotta
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.